Serotonin and pulmonary hypertension—from bench to bedside?

MacLean, M.R. and Dempsie, Y. (2009) Serotonin and pulmonary hypertension—from bench to bedside? Current Opinion in Pharmacology, 9(3), pp. 281-286. (doi: 10.1016/j.coph.2009.02.005)

Full text not currently available from Enlighten.

Publisher's URL: http://dx.doi.org/10.1016/j.coph.2009.02.005

Abstract

The serotonin hypothesis of pulmonary arterial hypertension (PAH) arose owing to anorexigens, acting as indirect serotinergic agonists, causing PAH. However, it is now thought that serotonin plays an important role in the pathobiology of PAH per se. The rate-limiting enzyme in the synthesis of peripheral serotonin is tryptophan hydroxylase 1 (TPH1), serotonin can mediate pulmonary arterial smooth muscle cell proliferation via the serotonin transporter (SERT) and serotonin can induce pulmonary vasoconstriction via the 5-HT1B receptor in man. There is evidence that TPH1, SERT and 5-HT1B expression/activity can be upregulated in clinical PAH. This review discusses recent evidence implicating serotonin in the development of experimental and clinical PAH and suggests potential therapeutic targets

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:MacLean, Professor Margaret and Dempsie, Dr Yvonne
Authors: MacLean, M.R., and Dempsie, Y.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
College of Medical Veterinary and Life Sciences
Journal Name:Current Opinion in Pharmacology
ISSN:1471-4892

University Staff: Request a correction | Enlighten Editors: Update this record